Clinical Trial · NCT00743353

Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5

Overview

The purpose of this research study is to get information from volunteers without cancer and patients with cancer who have received a new investigational study agent called, "\[F-18\] RGDK5," to evaluate biodistribution and dosimetry for the study agent and determine F-18 RGD-K5 uptake in angiogenic tumor. the system.

Sponsor

Unknown Organization

Phase

Early Phase 1

Contacts

Michael Yu, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT00743353

Drug / Compound

RGD-K5

Isotope(s):

Target(s):

αvβ3

Ligand Class: Peptides

Eligibility

Inclusion

For Normal Volunteers
Subject is capable of communicating with study personnelFor Cancer Subjects (same first four bullets as 'normals')
Subject is ≥ 18 years old at the time of investigational product administration (Subject is male or female of any race / ethnicity)
Subject is capable of complying with study procedures
Subject or subject's legally acceptable representative provides informed consent

Exclusion

Exclusion criteria not yet provided.